Target intelligence / Profile preview

CD2 molecule (CD2)

Target
CD2
Molecular classification
Immunoglobulin superfamily, Adhesion molecule, Receptor
01

Overview

CD2 is a transmembrane glycoprotein and a member of the immunoglobulin superfamily, found predominantly on the surface of T cells and natural killer (NK) cells[1][2][4]. It functions as both a cell adhesion molecule and a co-stimulatory receptor, critically involved in the formation and organization of the immunological synapse between T cells and antigen-presenting cells, primarily by binding to its ligand LFA-3 (CD58) in humans[1][2][4]. The interaction facilitates close contact and efficient signaling necessary for T-cell activation, proliferation, and immune response modulation[3][4]. CD2 is a diagnostic marker for T and NK cells and is implicated in diseases such as T-cell lymphomas, some autoimmune diseases, and infections. Therapeutically, monoclonal antibodies targeting CD2, such as siplizumab, are under investigation or clinical use for their immunosuppressive and anti-leukemic/lymphoma effects[4]. Safety issues with anti-CD2 therapies include increased infection risk due to T-cell depletion.

Other names
T-cell surface antigen CD2SRBCErythrocyte receptorLFA-2LFA-3 receptorRosette receptorT-cell surface antigen T11/Leu-5T11CD2 antigen (p50)Sheep red blood cell receptorLymphocyte-function antigen-2
02

Mechanism of action

Blocking T-cell activation via CD2–ligand (LFA-3/CD58) interaction; Modulation of T-cell costimulation and adhesion

03

Biological functions

Cell adhesionImmune responseT-cell activationCostimulationImmunological synapse formation
04

Disease associations

Cancer (notably T-cell lymphomas and leukemias)InfectionAutoimmune/inflammatory disease
05

Safety considerations

Lymphopenia (T-cell depletion with anti-CD2 therapeutics)Infectious risk due to immunosuppressionPotential for immunogenic reactions to therapeutic antibodies
06

Interacting drugs

Siplizumab (anti-CD2 monoclonal antibody)[4]

1 more in the full profile.

07

Biomarkers

T-cell and NK-cell marker in immunohistochemistry, especially to distinguish T-cell from B-cell lymphomas[2]

Beyond the preview

Go deeper on CD2 molecule (CD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD2 molecule (CD2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call